Oric Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel entitled Aiming for the Bull's Eye - Latest Advances in Targeted Oncology, and it's my great pleasure to have with me 4 distinguished expert speakers from IDEAYA Biosciences, Yujiro Hata, who is the CEO; from ORIC Pharmaceuticals, Jacob Chacko, also CEO; from Rain Therapeutics, Avanish Vellanki, Chairman and CEO; and last but not least, from Syndax Pharmaceuticals, Briggs Morrison, also CEO of the company. So welcome, gentlemen. Thank you very, very much for participating.
As a starting point, I think it would be great for those listeners less familiar with each of your pipelines for each of you to go through and just give a brief 2 to 3-minute overview of your company and the pipeline to level set the discussion. So, Avanish, you want to kick it off?
Sure. Happy to. And, Yigal, thanks for having
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |